Skip to main content
Evidence Snapshot

Calcium/calmodulin-dependent protein kinase type II subunit delta

CHEMBL2801 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T07:24:54Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2801
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Calcium/calmodulin-dependent protein kinase type II subunit delta as ChEMBL target CHEMBL2801, mapped to UniProt Q13557. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Calcium/calmodulin-dependent protein kinase type II subunit delta
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2801
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13557
Calcium/calmodulin-dependent protein kinase type II subunit delta
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Calcium/calmodulin-dependent protein kinase type II subunit delta matters

As of 2026-09-13

Calcium/calmodulin-dependent protein kinase type II subunit delta is reviewed as Calcium/calmodulin-dependent protein kinase type II subunit delta (UniProt Q13557); the current evidence base includes 16 approved drugs, 2021 compounds, and 303 assays, with lead potency reaching pChEMBL 10.5.

Protein context
Calcium/calmodulin-dependent protein kinase type II subunit delta

Calcium/calmodulin-dependent protein kinase type II subunit delta Sequence length is 499 aa.

Review this target as Calcium/calmodulin-dependent protein kinase type II subunit delta, mapped to UniProt Q13557. Sequence length is 499 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt Q13557 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 16 approved drugs, 2021 compounds, and 303 assays for this target. The dominant activity type is KI. CHEMBL388978 is the current potency anchor at pChEMBL 10.5.

Use CHEMBL388978 as the tractability anchor when discussing potency (pChEMBL 10.5).

Activity source · ChEMBL 36 via Core Engine
16 approved pChEMBL 10.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Calcium/calmodulin-dependent protein kinase type II subunit delta matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q13557, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2021
Total Compounds
303
Total Assays
16
Approved Drugs
IC50: 190.0, KI: 640.0, KD: 386.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL388978
 10.5 IC50 —
No preferred name
CHEMBL4218769
 10.3 IC50 —
No preferred name
CHEMBL4208018
 10.2 IC50 —
No preferred name
CHEMBL4215817
 10.2 IC50 —
No preferred name
CHEMBL4218245
 10.1 IC50 —

Approved Drugs

Structure Compound First Approval
MOMELOTINIB
CHEMBL1078178
 2023
FEDRATINIB
CHEMBL1287853
 2019
GILTERITINIB
CHEMBL3301622
 2018
ABEMACICLIB
CHEMBL3301610
 2017
BRIGATINIB
CHEMBL3545311
 2017
MIDOSTAURIN
CHEMBL608533
 2017
RIBOCICLIB
CHEMBL3545110
 2017
BARICITINIB
CHEMBL2105759
 2017
PALBOCICLIB
CHEMBL189963
 2015
RUXOLITINIB
CHEMBL1789941
 2011
SUNITINIB
CHEMBL535
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T07:24:54Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2801